Clinical trial · Observational
Application of Radiomics in the Diagnosis and Treatment Prediction of Pituitary Adenoma
Radiomics-based Diagnosis, Treatment and Outcome Prediction for Pituitary Adenoma
NCT06234553CI-TRIAL-00073694RIPAunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The images of patients with Pituitary adenoma were collected and analyzed based on the methods of radiomics.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pituitary Adenoma | Pituitary Neuroendocrine Tumor | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| surgery of pituitary adenomas | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- training set and validation set
- description
- Retrospective study focusing on the diagnosis and treatment outcomes of pituitary adenomas
- interventionNames
- Procedure: surgery of pituitary adenomas
Primary outcomes (1)
- measure
- Recurrence rate of pituitary adenoma
- timeFrame
- 1 year after treatment
- description
- The pituitary adenoma recurred 1 year after treatment. The recurrence was assessed by 3 aspects: (1)contrast enhanced MRI showed suspicious tumor growth, such as bone destruction; (2)signs and symptoms that had disappeared after treatment reappeared, such as pressing on nearby nerve tissue and some characteristic appearance; (3)endocrine indexes rose again after reaching the remission standard, iculding Prolactin(PRL)\>30 μg/L in Lactotroph adenoma; growth hormone (GH)\>2.5ng/ml in Somatotroph adenoma, serum cortisol\>800nmol/L at 8am in Corticotroph adenoma, while other types do not consider endocrine indicators.
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Gender unlimited, 18-80 years old; 2. Clinical diagnosis of Pituitary Adenoma and receive surgical treatment; 3. Received brain imaging; 4. informed consent signed Exclusion Criteria: 1. Pregnant / lactating women 2. Contraindications of imaging examination 3. Lack of effective clinical data 4. MRI data before treatment cannot be obtained 5. Postoperative pathology not revealed pituitary adenoma
References
Publications (0)
Data not yet available
No reference posted for this study.